Last Updated

03 Dec 2015

Clinical development of Pfs48/45 as transmission blocking vaccine

Objectives

Pfs48/45 is the most advanced EU-developed malaria TB vaccine candidate. PF10C is a subunit of Pfs48/45 that has been produced as R0-PF10C.  Immunization with 100% properly folded R0-PF10C induced transmission-blocking activity in 100% of immunized mice.

The objectives of REDMAL are:

1. Manufacture R0-PF10C at cGMP grade 

2. Prepare for clinical trials with R0-PF10C in Africa.

Principal Investigator

Date

2010 Mar - 2014 Nov

Total Project Funding

$1,151,000